Piramal Pharma, a multi-faceted pharmaceutical company, is poised to achieve its goal of reaching $2 billion in revenues and becoming one of the top 10 companies in its addressable markets by 2030, according to Chairperson Nandini Piramal. The company has been growing at a rate of 10-15% across its various business verticals over the past few years. In the last nine months of FY25, Piramal Pharma reported a growth of 14% compared to the same period in FY24, with revenues of ₹6,397 crore.
One of the company’s main growth drivers is its contract development and manufacturing (CDMO) business, which accounted for 58% of its revenues in FY24. The CDMO business has seen an 18% growth in the last three quarters and aims to grow to $1.2 billion with an EBITDA margin of 25% by 2030. The company’s CDMO business focuses on differentiated services and on-patent molecules, with a strong pipeline of over 150 projects across multiple phases, including 34% in Phase 3 clinical trials. Piramal expects at least half of these products to become commercial and offer long-term manufacturing opportunities for large pharma and emerging biotechs.
The company’s other business verticals, including complex hospital generics, India consumer healthcare, and a joint venture with Abbvie for ophthalmic products, are also performing well. With its global presence and diversified portfolio, Piramal Pharma is well-positioned to achieve its ambitious goals and solidify its position in the pharmaceutical industry.